Related Experiment Video
Updated: Sep 30, 2025
Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
Published on: October 14, 2019
Molecular Landscape of Small Bowel Adenocarcinoma
Karan Pandya1,2, Michael J Overman3, Pat Gulhati1,2
1Division of Medical Oncology, Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA.
Abstract:
Small bowel adenocarcinoma (SBA) is a rare malignancy, with lower incidence, later stage at diagnosis, and poor overall prognosis compared to other cancers of the gastrointestinal tract. Owing to the rarity of the disease along with the paucity of high-quality tissue samples and preclinical models, little is known about the molecular alterations characteristic of SBA. This is reflected by the fact that the clinical management of SBA is primarily extrapolated from colorectal cancer (CRC). Recent advances in genomic profiling have highlighted key differences between these tumors, establishing SBA as a molecularly unique intestinal cancer. Moreover, comprehensive molecular analysis has identified a relatively high incidence of potentially targetable genomic alterations in SBA, predictive of response to targeted and immunotherapies. Further advances in our knowledge of the mutational and transcriptomic landscape of SBA, guided by an increased understanding of the molecular drivers of SBA, will provide opportunities to develop novel diagnostic tools and personalized therapeutic strategies.
Insights
Small bowel adenocarcinoma (SBA) is a rare cancer. Genomic analysis reveals unique molecular features and potential therapeutic targets, differentiating it from colorectal cancer and paving the way for personalized treatments.
Area of Science:
- Gastroenterology
- Oncology
- Genomics
Background:
- Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy with poor prognosis.
- Limited understanding of SBA molecular alterations hinders effective treatment strategies.
- Current clinical management often relies on colorectal cancer protocols due to data scarcity.
Purpose of the Study:
- To investigate the molecular landscape of small bowel adenocarcinoma.
- To identify unique genomic alterations and potential therapeutic targets in SBA.
- To establish SBA as a distinct molecular entity within intestinal cancers.
Main Methods:
- Comprehensive genomic profiling of SBA tumors.
- Analysis of mutational and transcriptomic data.
- Comparison with colorectal cancer molecular profiles.
Main Results:
- SBA exhibits key molecular differences compared to colorectal cancer.
- A significant number of potentially targetable genomic alterations were identified in SBA.
- Genomic alterations in SBA may predict response to targeted and immunotherapies.
Conclusions:
- Small bowel adenocarcinoma is a molecularly unique intestinal cancer.
- Genomic insights offer opportunities for novel diagnostic tools and personalized therapies for SBA.
- Further research into SBA's molecular drivers is crucial for advancing treatment.
